Terpenoids from <i>Tripterygium hypoglaucum</i> and their inhibition of LPS-induced NO production

Zhao, Peng; Wang, Hao; Jin, Da-Qing; Ohizumi, Yasushi; Xu, Jing; Guo, Yuanqiang

doi:10.1080/09168451.2014.890035

Cited by 14 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is urgent to search for novel therapeutic reagents for ALI. The traditional Chinese medicine colquhounia root contains several alkaloids, terpenoids, lactones, and phenolic acids, such as triptolide and epicatechin [11]. Colquhounia root has several beneficial pharmacological properties, such as anti-inflammatory, immunosuppressive, antitumor, and analgesic activities [12–14].…”

Section: Introductionmentioning

confidence: 99%

Colquhounia Root Tablet Protects Rat Pulmonary Microvascular Endothelial Cells against TNF‐α‐Induced Injury by Upregulating the Expression of Tight Junction Proteins Claudin‐5 and ZO‐1

Zhou

Shi

Bai

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background There are currently limited effective pharmacotherapy agents for acute lung injury (ALI). Inflammatory response in the lungs is the main pathophysiological process of ALI. Our preliminary data have shown that colquhounia root tablet (CRT), a natural herbal medicine, alleviates the pulmonary inflammatory responses and edema in a rat model with oleic acid-induced ALI. However, the potential molecular action mechanisms underlining its protective effects against ALI are poorly understood. This study aimed to investigate the effects and mechanism of CRT in rat pulmonary microvascular endothelial cells (PMEC) with TNF-α-induced injury. Methods PMECs were divided into 6 groups: normal control, TNF-α (10 ng/mL TNF-α), Dex (1×10−6 M Dex + 10 ng/mL TNF-α), CRT high (1000 ng/mL CRT + 10 ng/mL TNF-α), CRT medium (500 ng/mL CRT + 10 ng/mL TNF-α), and CRT low group (250 ng/mL CRT + 10 ng/mL TNF-α). Cell proliferation and apoptosis were detected by MTT assay and flow cytometry. Cell micromorphology was observed under transmission electron microscope. The localization and expression of tight junction proteins Claudin-5 and ZO-1 were analyzed by immunofluorescence staining and Western blot, respectively. Results TNF-a had successfully induced an acute endothelial cell injury model. Dex and CRT treatments had significantly stimulated the growth and reduced the apoptosis of PMECs (all p < 0.05 or 0.01) and alleviated the TNF-α-induced cell injury. The expression of Claudin-5 and ZO-1 in Dex and all 3 CRT groups was markedly increased compared with TNF-a group (all p < 0.05 or 0.01). Conclusion CRT effectively protects PMECs from TNF-α-induced injury, which might be mediated via stabilizing the structure of tight junction. CRT might be a promising, effective, and safe therapeutic agent for the treatment of ALI.

show abstract

Section: Introductionmentioning

confidence: 99%

Colquhounia Root Tablet Protects Rat Pulmonary Microvascular Endothelial Cells against TNF‐α‐Induced Injury by Upregulating the Expression of Tight Junction Proteins Claudin‐5 and ZO‐1

Zhou

Shi

Bai

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Tripterygium wilfordii Hook.f. has been proved to have strong anti-inflammatory and immunosuppressive effects by many clinical and basic studies, which can significantly improve joint swelling and pain and delay bone destruction in patients with RA ( Zhang et al, 2007 ; Zhao et al, 2014 ; Xie et al, 2015 ; Chen et al, 2018 ). Ligustrum lucidum W.T.Aiton and its extract can improve bone metabolism and inhibit osteoclast differentiation so as to achieve the effect of anti-osteoporosis ( Chen et al, 2017 ).…”

Section: Discussionmentioning

confidence: 99%

Real-world effects of Yishen Tongbi decoction for rheumatoid arthritis: protocol for a prospective, observational, multicenter cohort study with validation against double-blind, randomized, controlled trial

Liu,

Zhu,

Xin

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Rheumatoid arthritis (RA) is a globally challenging and refractory autoimmune disease, constituting a serious menace to human health. RA is characterized by recurrent pain and is difficult to resolve, necessitating prolonged medication for control. Yishen Tongbi decoction is a traditional Chinese herbal compound prescribed for treating RA. We have completed a 3-year RCT study that confirmed the clinical efficacy of Yishen Tongbi decoction for RA. Notably, we observed a faster clinical remission rate compared to MTX by week 4 of treatment. In our forthcoming study, we intend to conduct a comprehensive assessment of the efficacy and safety of Yishen Tongbi decoction in the real-world treatment of RA through a prospective study.Methods and analysis: This prospective, multicenter, real-world observational study will be conducted at two designated centers in China from October 2023 to August 2025. The study will include 324 patients with active rheumatoid arthritis. One group will receive Yishen Tongbi decoction combined with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). The other group will receive standard treatment. Standard treatment can be further divided into subgroups: csDMARDs, targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), and biologic disease-modifying antirheumatic drugs (bDMARDs). In each group, the number of tender joints, number of swollen joints, pain score, patient global assessment, physician global assessment, disease activity index (DAS28-ESR or DAS28-CRP), clinical disease activity index (cDAI), simplified disease activity index (sDAI) and relevant laboratory data will be compared. Clinical indicators and disease activity of the patients will be assessed at baseline, week 4 and week 12 after the initiation of treatment. The primary outcome will be the American College of Rheumatology 20% improvement criteria (ACR20) attainment rate among patients at week 12 after treatment. Every adverse event will be reported.Ethics and dissemination: This study has been approved by the Ethics Committee of the first affiliated Hospital of Guangzhou University of traditional Chinese Medicine (NO.K-2023-009). The results of the study will be published in national and international peer-reviewed journals and at scientific conferences. The researchers will inform participants and other RA patients of the results through health education.Clinical Trial Registration:https://www.chictr.org.cn/index.html, identifier ChiCTR2300076073

show abstract

“…The majority of diterpenoids exhibit strong immunosuppressive and anti-inflammatory activities. The inhibitory activity towards LPS-induced NO production of these terpenoids was evaluated in microglial BV-2 cells, and all of the compounds showed inhibitory effects ( Zhao et al, 2014 ). Triptolide is a typical representative abietane terpenoid in THH, that has been reported to have diverse pharmacological effects such as anti-inflammatory, antiproliferative, proapoptotic, immunosuppression, and tumour inhibition effects, and this compound exhibits great efficacy in the treatment of rheumatoid arthritis, asthma, and Shin disease ( Shamon et al, 1997 ; Li J. et al, 2012 ; Chen S.-R. et al, 2018 ).…”

Section: Methodsmentioning

confidence: 99%

Tripterygium hypoglaucum (Lévl.) Hutch and Its Main Bioactive Components: Recent Advances in Pharmacological Activity, Pharmacokinetics and Potential Toxicity

et al. 2021

View full text Add to dashboard Cite

Tripterygium hypoglaucum (Lévl.) Hutch (THH) is believed to play an important role in health care and disease treatment according to traditional Chinese medicine. Moreover, it is also the representative of medicine with both significant efficacy and potential toxicity. This characteristic causes THH hard for embracing and fearing. In order to verify its prospect for clinic, a wide variety of studies were carried out in the most recent years. However, there has not been any review about THH yet. Therefore, this review summarized its characteristic of components, pharmacological effect, pharmacokinetics and toxicity to comprehensively shed light on the potential clinical application. More than 120 secondary metabolites including terpenoids, alkaloids, glycosides, sugars, organic acids, oleanolic acid, polysaccharides and other components were found in THH based on phytochemical research. All these components might be the pharmacological bases for immunosuppression, anti-inflammatory and anti-tumour effect. In addition, recent studies found that THH and its bioactive compounds also demonstrated remarkable effect on obesity, insulin resistance, fertility and infection of virus. The main mechanism seemed to be closely related to regulation the balance of immune, inflammation, apoptosis and so on in various disease. Furthermore, the study of pharmacokinetics revealed quick elimination of the main component triptolide. The feature of celastrol was also investigated by several models. Finally, the side effect of THH was thought to be the key for its limitation in clinical application. A series of reports indicated that multiple organs or systems including liver, kidney and genital system were involved in the toxicity. Its potential serious problem in liver was paid specific attention in recent years. In summary, considering the significant effect and potential toxicity of THH as well as its components, the combined medication to inhibit the toxicity, maintain effect might be a promising method for clinical conversion. Modern advanced technology such as structure optimization might be another way to reach the efficacy and safety. Thus, THH is still a crucial plant which remains for further investigation.

show abstract

Terpenoids from Tripterygium hypoglaucum and their inhibition of LPS-induced NO production

Cited by 14 publications

References 19 publications

Colquhounia Root Tablet Protects Rat Pulmonary Microvascular Endothelial Cells against TNF‐α‐Induced Injury by Upregulating the Expression of Tight Junction Proteins Claudin‐5 and ZO‐1

Colquhounia Root Tablet Protects Rat Pulmonary Microvascular Endothelial Cells against TNF‐α‐Induced Injury by Upregulating the Expression of Tight Junction Proteins Claudin‐5 and ZO‐1

Real-world effects of Yishen Tongbi decoction for rheumatoid arthritis: protocol for a prospective, observational, multicenter cohort study with validation against double-blind, randomized, controlled trial

Tripterygium hypoglaucum (Lévl.) Hutch and Its Main Bioactive Components: Recent Advances in Pharmacological Activity, Pharmacokinetics and Potential Toxicity

Contact Info

Product

Resources

About